scholarly journals The Relationship betweenHelicobacter pyloriand Beta-2 Microglobulin in Humans

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Abdullah Özgür Yeniova ◽  
Metin Kucukazman ◽  
Naim Ata ◽  
Kursat Dal ◽  
Ayşe Kefeli ◽  
...  
Keyword(s):  
Eradication Therapy ◽  
Gastrointestinal Diseases ◽  
Low Grade ◽  
Mhc I ◽  
Histocompatibility Complex ◽  
Before And After ◽  
Caga Status ◽  
H Pylori ◽  
Beta 2 Microglobulin ◽  
The Relationship

H. pyloriis related to various gastrointestinal diseases.β2Microglobulin (β2M) is an intrinsic element of major histocompatibility complex (MHC I). Serumβ2M level may increase in inflammatory states. The aim of current study is to evaluate the relationship betweenβ2M andH. pyloribearing CagA strains.Methods.H. pyloristatus was determined by histopathology of samples taken from stomach. CagA status andβ2M level were measured from blood samples of patients. Eradication therapy was administered to the patients withH. pyloriinfection.β2Microglobulin levels were measured before and after treatment.Results. 35 (29.2%)H. pylori(−) patients and 85 (70.8%)H. pylori(+) patients were included in the study. There were 52 (43.3%) patients with CagA negative and 33 (27.5%) patients with CagA positiveH. pyloriinfection. The mean serumβ2M level was 1.83 mg/L inH. pylori(−) group, 1.76 mg/L inH. pylori(+) CagA (−) group, and 1.93 mg/L inH. pyloriand CagA (+) group (P>0.05). Serumβ2M levels (1.82 versus 1.64 mg/LP<0.05) were decreased after eradication.Conclusion.H. pyloriand CagA status did not affectβ2M level. Relationship between low grade systematic inflammation andH. pylorishould be investigated to find out new predictors for diseases associated with inflammation.

scholarly journals The correlation between lncRNAs and Helicobacter pylori in gastric cancer

2019 ◽  
Vol 77 (9) ◽  
Author(s):  
Narges Dastmalchi ◽  
Seyed Mahdi Banan Khojasteh ◽  
Mirsaed Miri Nargesi ◽  
Reza Safaralizadeh
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
Molecular Mechanisms ◽  
Gastrointestinal Diseases ◽  
Mechanisms Of Action ◽  
Molecular Pathways ◽  
Gastric Diseases ◽  
Non Coding Rnas ◽  
H Pylori ◽  
The Relationship

ABSTRACT Helicobacter pylori infection performs a key role in gastric tumorigenesis. Long non-coding RNAs (lncRNAs) have demonstrated a great potential to be regarded as effective malignancy biomarkers for various gastrointestinal diseases including gastric cancer (GC). The present review highlights the relationship between lncRNAs and H. pylori in GC. Several studies have examined not only the involvement of lncRNAs in H. pylori-associated GC progression but also their molecular mechanisms of action. Among the pertinent studies, some have addressed the effects of H. pylori infection on modulatory networks of lncRNAs, while others have evaluated the effects of changes in the expression level of lncRNAs in H. pylori-associated gastric diseases, especially GC. The relationship between lncRNAs and H. pylori was found to be modulated by various molecular pathways.

scholarly journals White opaque substance visualized by magnifying narrow-band imaging is associated with intragastric acid conditions

2018 ◽  
Vol 06 (07) ◽  
pp. E830-E837 ◽  
Author(s):  
Kazumi Togo ◽  
Tetsuya Ueo ◽  
Kenshi Yao ◽  
Kurato Wada ◽  
Hideho Honda ◽  
...  
Keyword(s):  
Gastric Juice ◽  
Narrow Band ◽  
Narrow Band Imaging ◽  
Lipid Absorption ◽  
Before And After ◽  
Strong Acidity ◽  
Intragastric Acid ◽  
H Pylori ◽  
Ph Level ◽  
The Relationship

Abstract Background and study aims The presence of white opaque substance (WOS) is an endoscopic marker of intestinal metaplasia. Considering that the nature of WOS is absorbed lipid droplets, lipase plays an important role in the lipid absorption process and is inactivated at strong acidity. WOS may only be present in a hypochlorhydria state following Helicobacter pylori infection, and, thus, may not be highly sensitive marker, especially in H. pylori-eradicated patients. We investigated the relationship between WOS and gastric acid conditions. Patients and methods A total of 501 patients were retrospectively evaluated for the presence of WOS at 2 regions of interest using magnifying narrow-band imaging. The pH level of collected gastric juice was also measured. Study end points were (1) prevalence of WOS and its relationship with gastric juice pH in 3 groups: H. pylori-uninfected, H. pylori-infected, and H. pylori-eradicated; (2) the relationship between prevalence of WOS and gastric juice pH before and after proton pump inhibitor (PPI) administration in 29 H. pylori-eradicated cases. Results Prevalence of WOS was 0 % (0 /206), 28.4 % (31/109), and 3.2 % (6/186) in the H. pylori-uninfected, H. pylori-infected, and H. pylori-eradicated groups, respectively. Mean gastric juice pH was significantly higher in WOS-positive cases than in WOS-negative cases in the H. pylori-infected and H. pylori-eradicated groups (P < 0.0001). Mean gastric juice pH increased from 1.1 to 6.9 after PPI administration and WOS prevalence increased from 0 % (0/29) to 45 % (13/29) of cases. Conclusion The prevalence of WOS is closely associated with the neutralization of intragastric pH.

scholarly journals Pepsinogen II Can Be a Potential Surrogate Marker of Morphological Changes in Corpus before and afterH. pyloriEradication

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Sadegh Massarrat ◽  
Arghavan Haj-Sheykholeslami ◽  
Ashraf Mohamadkhani ◽  
Nasrin Zendehdel ◽  
Ali Aliasgari ◽  
...  
Keyword(s):  
Morphological Changes ◽  
Surrogate Marker ◽  
Pepsinogen I ◽  
Good Marker ◽  
Before And After ◽  
H Pylori ◽  
Lower Ratio ◽  
Gastric Cancer Patients ◽  
The Relationship ◽  
Pepsinogen Ii

Background.The aim of this investigation is to study the relationship between gastric morphology and serum biomarkers before and afterHelicobacter pylorieradication.Methods. First-degree relatives of gastric cancer patients underwent gastroscopy before and 2.5 years afterH. pylorieradication. The morphological changes in two categories (normal to mild and moderate to severe) were compared with level of pepsinogens I and II before eradication (n=369), after eradication (n=115), and in those with persistent infection (n=250).Results: After eradication, pepsinogen I decreased to 70% and pepsinogen II to 45% of the previous values. Unlike pepsinogen II and pepsinogen I to II ratio that were affected by the severity of inflammation and atrophy in corpus in all groups, pepsinogen I generally did not change. After eradication, subjects with high mononuclear infiltration in corpus had lower pepsinogen I (54 versus 77.1 μ/mL), higher pepsinogen II (9.4 versus 6.9 μ/mL), and lower ratio (7.9 versus 11.6) than those without (P<0.05).Conclusion. Pepsinogen II is a good marker of corpus morphological changes before and afterH. pylorieradication.

scholarly journals The Effects ofHelicobacter pyloriEradication on Proteinuria in Patients with Primary Glomerulonephritis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Bahar Caliskan ◽  
Halil Yazici ◽  
Yasar Caliskan ◽  
Yasemin Ozluk ◽  
Mine Gulluoglu ◽  
...  
Keyword(s):  
Iga Nephropathy ◽  
Eradication Therapy ◽  
Spontaneous Remission ◽  
Positive Staining ◽  
Stool Antigen Test ◽  
Protein Levels ◽  
Reactive Protein ◽  
Before And After ◽  
Stool Antigen ◽  
H Pylori

Background. Membranous nephropathy (MN) is a common cause of nephrotic syndrome. In most cases it is idiopathic, while it may also be secondary to many diseases. In this study, prevalence ofH. pyloriinfection and the effects ofH. pylorieradication on proteinuria levels were investigated.Methods. Thirty five patients with MN (19 male), 12 patients with IgA nephropathy (4 male) and 12 patients with focal segmental glomerulosclerosis (FSGS) (8 male) were studied. The presence ofH. pyloriantigen was investigated in renal tissues obtained by biopsy, and the effects ofH. pylorieradication on proteinuria levels were investigated.Results. Immunohistochemistry withH. pyloriantigen revealed no positive staining in the glomeruli of all patients. 19 patients (54%) with MN, 10 (83%) with IgA nephropathy and 4 (33%) with FSGS were positive forH. pyloristool antigen test(P=0.045). Patients withH. pyloriinfection were administered eradication therapy (lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days). Before the eradication therapy the mean proteinuria of patients with MN, IgA nephropathy and FSGS were 2.42 ± 3.24 g/day, 2.12 ± 1.63 g/day and 1.80 ± 1.32 g/day, respectively. Three months after eradication, baseline proteinuria levels of patients with MN significantly decreased to 1.26 ± 1.73 g/day(P=0.031). In all three groups there were no significant differences with regard to serum creatinine, albumin and C-reactive protein levels before and after eradication therapy.Conclusions. The eradication ofH. pyloriinfection may be effective to reduce proteinuria in patients with MN, while spontaneous remission of MN could not be excluded in this patient cohort. This trial is registered withNCT00983034.

scholarly journals Skin graft rejection by beta 2-microglobulin-deficient mice.

1992 ◽  
Vol 175 (4) ◽  
pp. 885-893 ◽  
Author(s):  
M Zijlstra ◽  
H Auchincloss ◽  
J M Loring ◽  
C M Chase ◽  
P S Russell ◽  
...  
Keyword(s):  
Skin Graft ◽  
Graft Rejection ◽  
Mutant Mice ◽  
Normal Numbers ◽  
M Gene ◽  
Class I Mhc ◽  
Mhc I ◽  
Histocompatibility Complex ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Mice homozygous for a beta 2-microglobulin (beta 2-m) gene disruption lack beta 2-m protein and are deficient for functional major histocompatibility complex class I (MHC-I) molecules. The mutant mice have normal numbers of CD4+8- T helper cells, but lack MHC-I-directed CD4-8+ cytotoxic T lymphocytes (CTLs). In this study we used the beta 2-m mutant mice to study the importance of MHC-I-directed immunity in skin graft rejection. Our results indicate that MHC-I-directed CD8+ CTLs are not essential in the rejection of allografts with whole MHC or multiple minor H differences. However, the absence of MHC-I-guided immunity profoundly reduces the ability of mutant mice to reject H-Y disparate grafts. In addition, we show that natural killer cells which vigorously reject MHC-I-deficient bone marrow grafts, are not effective in the destruction of MHC-I-deficient skin grafts.

Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates ofHelicobacter pylori

2014 ◽  
Vol 60 (1) ◽  
pp. 35-39 ◽  
Author(s):  
Eleonora Altman ◽  
Blair A. Harrison ◽  
Vandana Chandan ◽  
Robert Slinger
Keyword(s):  
Indirect Immunofluorescence ◽  
Enzyme Linked Immunosorbent Assay ◽  
Sugar Analysis ◽  
Potential Vaccine ◽  
Resistant Strains ◽  
Caga Status ◽  
H Pylori ◽  
The Relationship

Lipopolysaccharide (LPS) of Helicobacter pylori exhibits several unique structures, such as Lewis (Le) antigens, α-1,6-glucan, and dd-heptan. To investigate the relationship between LPS structure and resistance to clarithromycin, 41 Canadian isolates of H. pylori were characterized by whole-cell ELISA (enzyme-linked immunosorbent assay), sugar analysis, immunoblotting, and indirect immunofluorescence. The expression of type 2 Lewis X and (or) Lewis Y antigens was detected in 22 of 23 (95.7%) clarithromycin-resistant and in 14 of 18 (77.7%) clarithromycin-susceptible H. pylori strains (P < 0.05), and 8 isolates co-expressed type 1 and type 2 Le antigens (8/41, 19.5%). A significantly higher frequency of α-1,6-glucan (P < 0.01) was detected in clarithromycin-resistant strains than in clarithromycin-susceptible strains (19/23 (82.6%) versus 11/18 (61.1%)). Sugar analysis of selected α-1,6-glucan-positive H. pylori strains confirmed that they frequently contained elevated amounts of dd-heptose. Clarithromycin-resistant isolates were also characterized by low expression levels or absence of CagA (17/23, 73.9%). Indirect immunofluorescence studies carried out on selected H. pylori strains with rabbit immune sera specific for α-1,6-glucan confirmed broad recognition of α-1,6-glucan epitope. The binding was not affected by LPS glycotype of H. pylori isolates examined nor by their CagA status or resistance to clarithromycin. These findings suggest α-1,6-glucan as a potential vaccine target, especially in an era of increasing clarithromycin resistance in H. pylori.

scholarly journals Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura

2015 ◽  
Vol 8 (7) ◽  
pp. 35 ◽  
Author(s):  
Mohamadreza Amiri
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Eradication Therapy ◽  
Current Treatment ◽  
Thrombocytopenic Purpura ◽  
Stool Antigen Test ◽  
Platelet Counts ◽  
Before And After ◽  
History Of ◽  
H Pylori

<p>This study was a before and after clinical evaluation of <em>Helicobacter pylori</em> eradication on platelet counts in a group of 23 patients with chronic Idiopathic (Autoimmune) thrombocytopenic purpura (CITP). <em>H. pylori </em>infection was identified in patients by a <sup>13</sup>C-urea breath test and confirmed by an <em>H. pylori</em> stool antigen test. Eradication was conducted in patients testing positive. Infected (<em>n</em> = 10) and uninfected (<em>n</em> = 13) patient groups did not differ with respect to age, gender, history of previous splenectomy, treatment with anti-D, current treatment with corticosteroids, or initial platelet count<strong>s</strong>. <em>H pylori</em> eradication was successful in eight infected CITP patients, with two patients not responsive to treatment. Compared to the uninfected group, patients in the infected group who responded to eradication therapy had significantly increased platelet counts after six months (56.2 ± 22.2 <em>vs.</em> 233 ± 85.6 ×10<sup>3</sup> million cells/L; <em>P </em>&lt; 0.01), whereas platelet counts in the non-responding patients and uninfected group did not differ after this period of time. <em>H. pylori</em> eradication promotes significant platelet count improvement in patients with CITP. Thus, all patients with CITP should be tested and treated for<em> H. pylori </em>infections.</p>

A novel monoclonal stool antigen test for the detection of H. pylori before and after eradication therapy: A prospective study in outpatients

2003 ◽  
Vol 124 (4) ◽  
pp. A177 ◽  
Author(s):  
Vincens Weingart ◽  
Holger Ruessmann ◽  
Sibylle Koletzko ◽  
Josef Weingart ◽  
Wilhelm Hoechter ◽  
...  
Keyword(s):  
Prospective Study ◽  
Eradication Therapy ◽  
Antigen Test ◽  
Stool Antigen Test ◽  
Before And After ◽  
Stool Antigen ◽  
H Pylori ◽  
A Prospective Study

scholarly journals Two Enzyme Immunoassays and PCR for Detection ofHelicobacter pylori in Stool Specimens from Pediatric Patients before and after Eradication Therapy

2000 ◽  
Vol 38 (10) ◽  
pp. 3710-3714 ◽  
Author(s):  
Athanasios Makristathis ◽  
Wolfgang Barousch ◽  
Eva Pasching ◽  
Christa Binder ◽  
Christa Kuderna ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Eradication Therapy ◽  
Test Series ◽  
Diagnostic Tools ◽  
The Novel ◽  
Enzyme Immunoassays ◽  
End Of Treatment ◽  
Before And After ◽  
Stool Samples ◽  
H Pylori

This study of pediatric patients was intended to determine the suitability of stool PCR and two antigen enzyme immunoassays (EIAs; Premier Platinum HpSA and the novel FemtoLab H. pylori), which detectHelicobacter pylori antigens in feces, as pretreatment diagnostic tools and especially as posttreatment control. Forty-nineH. pylori-infected children with dyspepsia received eradication therapy. Successful treatment was determined by a negative [13C]urea breath test 4 and 12 weeks after discontinuation of therapy. Fecal specimens were collected prior to eradication therapy as well as 4 weeks after the end of treatment. Successfully treated children delivered stool samples at 6, 8, and 12 weeks posttreatment also. Specimens were examined by seminested PCR and Premier Platinum HpSA and were reexamined by both EIAs as soon as FemtoLab H. pylori was available. In the first test series, the overall sensitivities of PCR and Premier Platinum HpSA were 93.0 and 91.1%, respectively. With specimens collected at 4 weeks after treatment, the respective specificities were 68.8 and 79.3%. After longer follow-up periods, however, they gradually increased to 100 and 96.9%, respectively. In the new test series, Premier Platinum HpSA delivered a considerably lower number of false-positive results (4 versus 18), indicating intertest variations. The overall test sensitivity was 94.6%, and the overall specificity was 97.5%. FemtoLab H. pylori showed an excellent performance with an overall sensitivity and specificity of 98.2 and 98.1%, respectively. Thus, in contrast to PCR, both EIAs were shown to be suitable for early posttreatment control.

scholarly journals Diseases of the oral mucosa associated with Helicobacter pylori

2020 ◽  
Vol 24 (6) ◽  
pp. 399-405
Author(s):  
Svetlana V. Tarasenko ◽  
M. A. Stepanov ◽  
S. A. Kalinin ◽  
V. V. Morozova
Keyword(s):  
Helicobacter Pylori ◽  
Periodontal Disease ◽  
Oral Mucosa ◽  
Gastrointestinal Diseases ◽  
Stage Duration ◽  
H Pylori ◽  
The Relationship

This study analyzed the role of Helicobacter pylori in the development of lesions of the oral mucosa and explored the relationship between the prevalence and intensity of periodontal disease and the stage, duration, and severity of gastrointestinal diseases associated with H. pylori infection. The newly identified factors of H. pylori pathogenicity that participate in the development of lesions of the oral mucosa in case of a body infection were also determined.

Sign in / Sign up

Export Citation Format

Share Document